Safety of paclitaxel-coated devices in peripheral artery disease

Although an unplanned, interim analysis from an ongoing randomized trial in Sweden has suggested no significant difference in mortality between patients with peripheral artery disease receiving paclitaxel-coated devices and those receiving uncoated devices for lower-extremity revascularization, the analysis did not resolve the question of whether paclitaxel-coated devices are safe for these patients.

Automated summary

An unplanned interim analysis from a randomized trial in Sweden found no significant difference in mortality between peripheral artery disease patients receiving paclitaxel-coated devices and those receiving uncoated devices for lower-extremity revascularization, but did not definitively answer the safety question regarding paclitaxel-coated devices.